SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, tod
Aethlon Medical press release (NASDAQ:AEMD): FQ3 GAAP EPS of -$0.16 misses by $0.02.Revenue of $0.02M (-96.8% Y/Y) misses by $0.19M.
Aethlon Medical's (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Aethlon Medical Q3 2022 Earnings Preview (NASDAQ:AEMD)

10:35pm, Friday, 11'th Feb 2022 Seeking Alpha
Aethlon Medical (NASDAQ:AEMD) is scheduled to announce Q3 earnings results on Monday, February 14th, after market close.The consensus EPS Estimate is -$0.14 (+30.0% Y/Y) and the
DUBLIN , Feb. 7, 2022 /PRNewswire/ -- The "Global Blood Purification Equipment Market 2021-2031 by Product (Hemodialysis, Blood Filtration, CRRT, Hemoperfusion, Plasma Exchange Device), Portability (Portable, Stationary), Indication, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com''s offering. The global blood purification equipment market will reach $21.08 billion by 2031, growing by 5.5% annually over 2021-2031, driven by the increasing prevalence of blood-related diseases, rising geriatric population, technological innovations, growing healthcare expenditure, rising adoption of home based healthcare, and the rising health consciousness amid COVID-19 pandemic. This report is based on a comprehensive research of the entire global blood purification equipment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it
Longview Acquisition Corp. II (NYSE:LGV) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk. Analyst Ratings This is a breakdown of current recommendations and price targets for []

-$0.13 EPS Expected for Aethlon Medical, Inc. (NASDAQ:AEMD) This Quarter

09:26pm, Thursday, 16'th Dec 2021 Transcript Daily
Wall Street analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aethlon Medicals earnings. Aethlon Medical reported earnings of ($0.20) per share in the same quarter last year, which suggests a positive year-over-year growth []
Wall Street analysts expect that Aethlon Medical, Inc. (NASDAQ:AEMD) will announce $260,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aethlon Medicals earnings. The highest sales estimate is $400,000.00 and the lowest is $110,000.00. Aethlon Medical reported sales of $630,000.00 in the same quarter last year, which []
Geode Capital Management LLC boosted its stake in Aethlon Medical, Inc. (NASDAQ:AEMD) by 54.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 103,121 shares of the medical equipment providers stock after purchasing an additional 36,368 shares during the period. Geode Capital Management LLC owned about 0.67% of []

Analysts Expect Aethlon Medical, Inc. (NASDAQ:AEMD) to Post -$0.13 EPS

11:52pm, Friday, 26'th Nov 2021 Dakota Financial News
Equities analysts forecast that Aethlon Medical, Inc. (NASDAQ:AEMD) will post earnings of ($0.13) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aethlon Medicals earnings. Aethlon Medical posted earnings of ($0.20) per share in the same quarter last year, which indicates a positive year over year []
Wall Street analysts expect that Aethlon Medical, Inc. (NASDAQ:AEMD) will post ($0.18) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Aethlon Medicals earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.13). Aethlon Medical posted earnings per share of ($0.20) in the same quarter []
Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE